Infectious Disorders - Drug Targets

Author(s): Mandeep Kaur*, Rahul Sandhu and Akriti Aggarwal

DOI: 10.2174/0118715265298816240321045741

DownloadDownload PDF Flyer Cite As
Recombinant ACE2 - Opportunities and Challenges in COVID-19 Treatment

Article ID: e180424229061 Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

It was in 2019 that the world experienced the devastation caused by SARS-CoV-2, contributing to a large number of deaths. This contagious virus not only challenged the health care system but has also hit the economy very badly. There has been a lot of research on effective vaccine development, and there has been some success in the same, but no effective antiviral drugs are available in the market. No doubt vaccination can prevent the disease, but it doesn’t have the potential to cure an infected person, for which there is a dire need to develop some effective drug. Angiotensin convertase enzyme 2 (ACE2) played a substantial role in SARS-CoV-2 pathogenesis and thus has gained much attention during the pandemic. Moreover, it has opened up new avenues for the cure of COVID-19.

Keywords: SARS-CoV-2, COVID-19, ACE2 downregulation, Kupffer cells, hepatocytes, COVID-19 treatment.